Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.

Authors: Walter, MJ  Ding, L  Shen, D  Shao, J  Grillot, M  McLellan, M  Fulton, R  Schmidt, H  Kalicki-Veizer, J  O'Laughlin, M  Kandoth, C  Baty, J  Westervelt, P  DiPersio, JF  Mardis, ER  Wilson, RK  Ley, TJ  Graubert, TA 
Citation: Walter MJ, etal., Leukemia. 2011 Jul;25(7):1153-8. doi: 10.1038/leu.2011.44. Epub 2011 Mar 18.
Pubmed: (View Article at PubMed) PMID:21415852
DOI: Full-text: DOI:10.1038/leu.2011.44

Alterations in DNA methylation have been implicated in the pathogenesis of myelodysplastic syndromes (MDS), although the underlying mechanism remains largely unknown. Methylation of CpG dinucleotides is mediated by DNA methyltransferases, including DNMT1, DNMT3A and DNMT3B. DNMT3A mutations have recently been reported in patients with de novo acute myeloid leukemia (AML), providing a rationale for examining the status of DNMT3A in MDS samples. In this study, we report the frequency of DNMT3A mutations in patients with de novo MDS, and their association with secondary AML. We sequenced all coding exons of DNMT3A using DNA from bone marrow and paired normal cells from 150 patients with MDS and identified 13 heterozygous mutations with predicted translational consequences in 12/150 patients (8.0%). Amino acid R882, located in the methyltransferase domain of DNMT3A, was the most common mutation site, accounting for 4/13 mutations. DNMT3A mutations were expressed in the majority of cells in all tested mutant samples regardless of myeloblast counts, suggesting that DNMT3A mutations occur early in the course of MDS. Patients with DNMT3A mutations had worse overall survival compared with patients without DNMT3A mutations (P=0.005) and more rapid progression to AML (P=0.007), suggesting that DNMT3A mutation status may have prognostic value in de novo MDS.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11041122
Created: 2016-03-22
Species: All species
Last Modified: 2016-03-22
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.